RANI (ranitherapeutics.com) רווחיות מכירות לפי רווח גולמי

Rani Therapeutics is developing the innovative RaniPill capsule, which replaces injections with intestinal micro-injections. The gross margin exhibits volatility, as business success depends on the bioavailability of oral drugs. However, clinical trial delays and costly cash burn create risks. The value of 90.20 shows the current volume of the metric, capturing deviations of direct costs from the norm.
פילוחי מדדים פיננסיים ומדדי שוק עבור ranitherapeutics.com (RANI)

Gross margin measures the portion of revenue remaining after covering direct production costs, allowing for an assessment of capital management efficiency and the asset's pricing power. The in-house production of injectable capsules by Rani Therapeutics (RANI) reduces reliance on third-party factories, and an analysis of gross margin stability helps determine the extent to which such integration protects profits from cost volatility and ensures investment sustainability.